Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding
Others
Ratios

Viking Therapeutics (VKTX) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $7.1 million.

  • Viking Therapeutics' Other Non Operating Income fell 3460.86% to $7.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $33.7 million, marking a year-over-year decrease of 1771.33%. This contributed to the annual value of $33.7 million for FY2025, which is 1771.33% down from last year.
  • Latest data reveals that Viking Therapeutics reported Other Non Operating Income of $7.1 million as of Q4 2025, which was down 3460.86% from $7.8 million recorded in Q3 2025.
  • Viking Therapeutics' 5-year Other Non Operating Income high stood at $11.8 million for Q2 2024, and its period low was $142000.0 during Q1 2022.
  • Moreover, its 5-year median value for Other Non Operating Income was $4.6 million (2023), whereas its average is $4.6 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first plummeted by 8452.61% in 2021, then skyrocketed by 216884.42% in 2023.
  • Over the past 5 years, Viking Therapeutics' Other Non Operating Income (Quarter) stood at $154000.0 in 2021, then soared by 370.13% to $724000.0 in 2022, then soared by 546.41% to $4.7 million in 2023, then soared by 131.22% to $10.8 million in 2024, then plummeted by 34.61% to $7.1 million in 2025.
  • Its Other Non Operating Income stands at $7.1 million for Q4 2025, versus $7.8 million for Q3 2025 and $9.0 million for Q2 2025.